ReviewAustralian prescriber2023
Ongoing challenges of off-label prescribing.
Review in Australian prescriber, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?The Medical journal of Australia · 2026Article
- Polypharmacy in Pediatric Palliative Care: Exploring Discrepancies Between Physicians and Pharmacists.Children (Basel, Switzerland) · 2025Article
- Therapeutic vapes for smoking cessation and nicotine dependence.Australian prescriber · 2024Review
- Medicines Repurposing Program - supporting new uses for existing medicines.Australian prescriber · 2024Article
- Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22).Harm reduction journal · 2024Article
- Co-design of a paediatric oncology medicines database (ProCure) to support complex care provision for children with a hard-to-treat cancer.Frontiers in medicine · 2024Article
- Ongoing challenges of off-label prescribing.Australian prescriber · 2023Review
- Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital.Journal of clinical medicine · 2021Article
- Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study.Journal of clinical medicine · 2021Article
- Evolving evidence for immunosuppressants in COVID-19.Australian prescriber · 2021Article
- The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review.PloS one · 2021Article
- Immunosuppression for COVID-19: repurposing medicines in a pandemic.Australian prescriber · 2020Article
- Ethics codes and use of new and innovative drugs.British journal of clinical pharmacology · 2019Review
- Neuropathic pain - definition and drug therapy.Australian prescriber · 2018Article
- It is time to review how unlicensed medicines are used.European journal of clinical pharmacology · 2015Review
- Outcomes of off-label drug uses in hospitals: a multicentric prospective study.European journal of clinical pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Off-label prescribing refers to prescribing that is not concordant with the indications, doses, routes of administration or patient groups included in the Australian approved product information. Off-label prescribing is common, especially for vulnerable patient groups who tend to be excluded from clinical trials, such as children and pregnant women. There may be increased risk of prescriber liability if the patient experiences an adverse event following off-label prescription, particularly when supporting evidence or guidelines are lacking. There may be additional costs to the patient if the medicine is not subsidised for the off-label indication. Prescribers should ensure patients are aware when a medicine is being prescribed off label, and informed of potential benefits and harms. Alternative pathways for approval of new indications, doses and patient groups may reduce the need for off-label prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.